...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
【24h】

Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.

机译:水杨酸衍生物对TNF-α依赖性NFκB活性抑制的构效关系:对N-(5-氯水杨酰)苯乙胺对实验性结肠炎的抗炎作用的暗示。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To develop a more potent NFκB inhibitor from salicylic acid which is known to inhibit activity of NFκB, a transcription factor regulating genes involved in immunity, inflammation and tumorigenesis, derivatives of salicylic acid (SA) where the 5 position, carboxyl or hydroxyl group was modified were treated in HCT116 cells transfected with an NFκB dependent luciferase gene and LPS-stimulated RAW264.7 cells. Amidation of the carboxylic group or substitution of chlorine at the 5 position increased the ability of SA to suppress the expression of NFκB dependent luciferase and inducible nitric oxide synthase, a product of an NFκB target gene. Moreover, simultaneous amidation and chlorination of SA (5-chlorosalicylamide; 5-CSAM) conferred an additive NFκB inhibitory activity on SA. To further enhance the inhibitory activity, N-modification was imposed on 5-CSAM. N-(5-chlorosalicyloyl)phenethylamine (5-CSPA), N-(5-chlorosalicyloyl)3-phenylpropylamine (5-CSPPA) and N-(5-chlorosalicyloyl)4-hydroxyphenylethylamine (5-CSHPA) showed greater potencies for inhibiting NFκB activity than other derivatives. Their IC(50)s' in the luciferase assay measured 15μM (5-CSPA), 17μM (5-CSPPA) and 91μM (5-CSHPA). Rectal administration of 5-CSPA ameliorated TNBS-induced rat colitis, which was more effective than a conventional drug, 5-aminosalicylic acid. These data may provide useful information for development of a therapeutic agent for treatment of diseases where NFκB plays a critical role in the pathogenic progresses.
机译:为了从水杨酸开发更有效的NFκB抑制剂,已知它可以抑制NFκB的活性,NFκB是一种调节免疫,炎症和肿瘤发生的转录因子调节基因,是水杨酸(SA)的衍生物,其中5位,羧基或羟基被修饰在转染有NFκB依赖性荧光素酶基因的HCT116细胞和LPS刺激的RAW264.7细胞中进行了处理。羧基的酰胺化或5位上的氯取代增强了SA抑制NFκB依赖的荧光素酶和NFκB靶基因产物诱导型一氧化氮合酶表达的能力。此外,SA(5-氯水杨酰胺; 5-CSAM)的同时酰胺化和氯化反应赋予SANFκB加性抑制活性。为了进一步提高抑制活性,对5-CSAM进行了N-修饰。 N-(5-氯水杨酰基)苯乙胺(5-CSPA),N-(5-氯水杨酰基)3-苯丙胺(5-CSPPA)和N-(5-氯水杨酰基)4-羟基苯乙胺(5-CSHPA)显示出更大的抑制力NFκB活性高于其他衍生物。萤光素酶测定中的IC(50)s分别为15μM(5-CSPA),17μM(5-CSPPA)和91μM(5-CSHPA)。直肠给药5-CSPA可改善TNBS诱导的大鼠结肠炎,它比常规药物5-氨基水杨酸更有效。这些数据可为开发用于治疗其中NFκB在致病性进程中起关键作用的疾病的治疗剂提供有用的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号